1、 GUR S,WEIZMAN S,HERMESH H,et al.Comparison of medical treatment of patients with schizophrenia in general practitioners' clinics versus mental health clinics:A cohort study[J].J Psychosom Res,2023(171):111383. GUR S,WEIZMAN S,HERMESH H,et al.Comparison of medical treatment of patients with schizophrenia in general practitioners' clinics versus mental health clinics:A cohort study[J].J Psychosom Res,2023(171):111383.
2、 BARRO M,YAMéOGO A R,MBA R D,et al.Modelling factors associated with therapeutic inertia in hypertensive patients:Analysis using repeated data from a hospital registry in West Africa[J].Medicine(Baltimore),2022,101(49):e31147. BARRO M,YAMéOGO A R,MBA R D,et al.Modelling factors associated with therapeutic inertia in hypertensive patients:Analysis using repeated data from a hospital registry in West Africa[J].Medicine(Baltimore),2022,101(49):e31147.
3、 LIAO C T,TOH H S,SUN L,et al.Cost-effectiveness of intensive vs standard blood pressure control among older patients with hypertension[J].JAMA Netw Open,2023,6(2):e230708. LIAO C T,TOH H S,SUN L,et al.Cost-effectiveness of intensive vs standard blood pressure control among older patients with hypertension[J].JAMA Netw Open,2023,6(2):e230708.
4、 HALLER H,BIANCHI S,MCCAFFERTY K,et al.Safety and efficacy of patiromer in hyperkalemic patients with CKD:A pooled Analysis of three randomized trials[J].Kidney360,2022,3(12):2019-2026. HALLER H,BIANCHI S,MCCAFFERTY K,et al.Safety and efficacy of patiromer in hyperkalemic patients with CKD:A pooled Analysis of three randomized trials[J].Kidney360,2022,3(12):2019-2026.
5、 MOUSA S I,NYBERG F,HAJIEBRAHIMI M,et al.Initiation of antihypertensive drugs to patients with confirmed COVID-19-A population-based cohort study in Sweden[J].Basic Clin Pharmacol Toxicol,2022,131(3):196-204. MOUSA S I,NYBERG F,HAJIEBRAHIMI M,et al.Initiation of antihypertensive drugs to patients with confirmed COVID-19-A population-based cohort study in Sweden[J].Basic Clin Pharmacol Toxicol,2022,131(3):196-204.
6、 SONABEND A M,GOULD A,AMIDEI C,et al.Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma:A phase 1 trial[J].Lancet Oncol,2023,24(5):509-522. SONABEND A M,GOULD A,AMIDEI C,et al.Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma:A phase 1 trial[J].Lancet Oncol,2023,24(5):509-522.
7、 MACHADO T R L,de PáDUA C A M,de MIRANDA DRUMMOND P L,et al.Factors associated with potentially inappropriate medications in elderly with multiple myeloma[J].J Oncol Pharm Pract,2023:10781552231190009. MACHADO T R L,de PáDUA C A M,de MIRANDA DRUMMOND P L,et al.Factors associated with potentially inappropriate medications in elderly with multiple myeloma[J].J Oncol Pharm Pract,2023:10781552231190009.
8、 MOUTCHIA J,MCCLELLAND R L,AL-NAAMANI N,et al.Minimal clinically important difference in the 6-minute-walk distance for patients with pulmonary arterial hypertension[J].Am J Respir Crit Care Med,2023,207(8):1070-1079. MOUTCHIA J,MCCLELLAND R L,AL-NAAMANI N,et al.Minimal clinically important difference in the 6-minute-walk distance for patients with pulmonary arterial hypertension[J].Am J Respir Crit Care Med,2023,207(8):1070-1079.
9、 PLATZBECKER U,DELLA PORTA M G,SANTINI V,et al.Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive,transfusion-dependent,lower-risk myelodysplastic syndromes(COMMANDS):Interim analysis of a phase 3,open-label,randomised controlled trial[J].Lancet,2023,402(10399):373-385. PLATZBECKER U,DELLA PORTA M G,SANTINI V,et al.Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive,transfusion-dependent,lower-risk myelodysplastic syndromes(COMMANDS):Interim analysis of a phase 3,open-label,randomised controlled trial[J].Lancet,2023,402(10399):373-385.
10、 YONG K,WILSON W,de TUTE R M,et al.Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales(CARDAMON):A randomised,phase 2,non-inferiority trial[J].Lancet Haematol,2023,10(2):e93-e106. YONG K,WILSON W,de TUTE R M,et al.Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales(CARDAMON):A randomised,phase 2,non-inferiority trial[J].Lancet Haematol,2023,10(2):e93-e106.
11、 STRICKLER J H,CERCEK A,SIENA S,et al.Tucatinib plus trastuzumab for chemotherapy-refractory,HER2-positive,RAS wild-type unresectable or metastatic colorectal cancer(MOUNTAINEER):A multicentre,open-label,phase 2 study[J].Lancet Oncol,2023,24(5):496-508. STRICKLER J H,CERCEK A,SIENA S,et al.Tucatinib plus trastuzumab for chemotherapy-refractory,HER2-positive,RAS wild-type unresectable or metastatic colorectal cancer(MOUNTAINEER):A multicentre,open-label,phase 2 study[J].Lancet Oncol,2023,24(5):496-508.
12、 SWEENEY C J,MARTIN A J,STOCKLER M R,et al.Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer(ENZAMET):An international,open-label,randomised,phase 3 trial[J].Lancet Oncol,2023,24(4):323-334. SWEENEY C J,MARTIN A J,STOCKLER M R,et al.Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer(ENZAMET):An international,open-label,randomised,phase 3 trial[J].Lancet Oncol,2023,24(4):323-334.
13、 MICHAEL M,GROOTHOFF J W,SHASHA-LAVSKY H,et al.Lumasiran for advanced primary hyperoxaluria type 1:Phase 3 ILLUMINATE-C trial[J].Am J Kidney Dis,2023,81(2):145-155. MICHAEL M,GROOTHOFF J W,SHASHA-LAVSKY H,et al.Lumasiran for advanced primary hyperoxaluria type 1:Phase 3 ILLUMINATE-C trial[J].Am J Kidney Dis,2023,81(2):145-155.
14、 JA?S X,BRENOT P,BOUVAIST H,et al.Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension(RACE):A multicentre,phase 3,open-label,randomised controlled trial and ancillary follow-up study[J].Lancet Respir Med,2022,10(10):961-971. JA?S X,BRENOT P,BOUVAIST H,et al.Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension(RACE):A multicentre,phase 3,open-label,randomised controlled trial and ancillary follow-up study[J].Lancet Respir Med,2022,10(10):961-971.
15、 中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.老年高血压的诊断与治疗中国专家共识(2011版)[J].中华内科杂志,2012,51(1):76-82. 中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.老年高血压的诊断与治疗中国专家共识(2011版)[J].中华内科杂志,2012,51(1):76-82.
16、 王增武,王文.中国高血压防治指南(2018年修订版)解读[J].中国心血管病研究,2019,17(3):193-197. 王增武,王文.中国高血压防治指南(2018年修订版)解读[J].中国心血管病研究,2019,17(3):193-197.
17、 SARRAJU A,BAKRIS G,CANNON C P,et al.Cardiovascular effects of canagliflozin in relation to renal function and albuminuria[J].J Am Coll Cardiol,2022,80(18):1721-1731. SARRAJU A,BAKRIS G,CANNON C P,et al.Cardiovascular effects of canagliflozin in relation to renal function and albuminuria[J].J Am Coll Cardiol,2022,80(18):1721-1731.
18、 SUGAWARA S,KONDO M,YOKOYAMA T,et al.Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer:First results from the phase 2 J-ALTA study[J].Int J Clin Oncol,2022,27(12):1828-1838. SUGAWARA S,KONDO M,YOKOYAMA T,et al.Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer:First results from the phase 2 J-ALTA study[J].Int J Clin Oncol,2022,27(12):1828-1838.
19、 GNANENTHIRAN S R,BORGHI C,BURGER D,et al.Renin-angiotensin system inhibitors in patients with COVID-19:A meta-analysis of randomized controlled trials led by the international society of hypertension[J].J Am Heart Assoc,2022,11(17):e026143. GNANENTHIRAN S R,BORGHI C,BURGER D,et al.Renin-angiotensin system inhibitors in patients with COVID-19:A meta-analysis of randomized controlled trials led by the international society of hypertension[J].J Am Heart Assoc,2022,11(17):e026143.
20、 O'BRIEN M,PAZ-ARES L,MARREAUD S,et al.Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer(PEARLS/KEYNOTE-091):An interim analysis of a randomised,triple-blind,phase 3 trial[J].Lancet Oncol,2022,23(10):1274-1286. O'BRIEN M,PAZ-ARES L,MARREAUD S,et al.Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer(PEARLS/KEYNOTE-091):An interim analysis of a randomised,triple-blind,phase 3 trial[J].Lancet Oncol,2022,23(10):1274-1286.
21、 MACKENZIE I S,ROGERS A,POULTER N R,et al.Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK(TIME study):A prospective,randomised,open-label,blinded-endpoint clinical trial[J].Lancet,2022,400(10361):1417-1425. MACKENZIE I S,ROGERS A,POULTER N R,et al.Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK(TIME study):A prospective,randomised,open-label,blinded-endpoint clinical trial[J].Lancet,2022,400(10361):1417-1425.
